12:00 AM
Jul 15, 2002
 |  BioCentury  |  Product Development

Countdown on Avastin

With the biotech sector desperate for positive product news, attention will be turning to Avastin from Genentech Inc., which is aiming to disclose its first Phase III data by the end of the quarter, in breast cancer.

Thus the anti-VEGF antibody was a predictable focus of DNA's earnings conference call last week. In its update, the company was careful to note that the first data will come from what it considers the higher-risk indication, metastatic breast cancer.


Read the full 377 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >